Evercore Upgrades DexCom to Outperform, Citing Strong Growth Outlook Through 2028

Key Facts

1Evercore ISI upgraded DexCom (DXCM) to Outperform from In Line and set a $90 price target.

2Evercore expects double-digit revenue growth and more than 200 basis points of annual margin expansion through 2028.

3The estimated earnings per share compound annual growth rate for the company is approximately 25%.

Evercore ISI has upgraded DexCom (DXCM) from In Line to Outperform, setting a new price target of $90 per share. The upgrade is supported by expectations of double-digit revenue growth and annual margin expansion exceeding 200 basis points through 2028. Analysts estimate the company’s earnings per share (EPS) will achieve a compound annual growth rate of approximately 25% based on the new projections. Key drivers for this optimistic outlook include advancements in automated delivery systems and expanded coverage for non-insulin-treated Type 2 diabetes. Evercore highlighted the potential for significant operational leverage as a primary catalyst for the rating change. This positive assessment positions DexCom as a strong contender in the medical devices sector over the next several years.

Open on chart